Internal research portal for Sator's precision oncolytic virotherapy platform. Eight years of systematic screening, interactive analytics, and generated reports.
Interactive tools for the 96-line × 38-virus screening panel. 6,317 data points across 9 cancer types, 8 years (2018–2026).
96 cell lines × 38 viruses. Toggle basal/+IFNβ, predictions, IFN sensitivity. Receptor expression with 6-tier data sourcing. Chumakov 2018 IFN integrity panel (28 genes). Colorblind-safe mode.
2018–2026Dose-response curves for every virus × cell line combination. Singles across all 103 lines; 11 multi-virus combos run on 10 mesothelioma + control lines only. 7 dilution points (10⁻² to 10⁻⁸), basal and +IFNβ. Compare profiles, overlay curves, filter by cancer type.
2019–2021Standalone experiment. 46 cell lines ranked by IFN-β fold-change. Dose-response sparklines. 4-tier sensitivity zones. 4 corrected from raw plate data.
Oct 20214-virus pairwise combinations on mesothelioma. Kill heatmap, dose-response curves, Bliss synergy analysis, PBMC safety.
2018–2026Three simplified views of the primary screen: traffic-light scorecard for executives, ranked virus selector for clinicians, condensed poster heatmap.
2019–2021Dedicated experiment. 46 cell lines, 5 cancer types. Dose-response fold-change ranking. 4 values corrected from raw plate data. Zone classification.
2019–2021Per-cancer-type IFN analysis, CDx implications, monotherapy vs. combination strategy, indication prioritization.
Oct 20214 lead viruses × all pairwise combos. Additive basal, dramatic synergy under IFN (+69pp). CoxA7 PBMC-safe.
First-party RNA-seq, receptor correlations, IFN integrity mapping, protease processing, and molecular characterization.
16 genes (15 receptors + CXCL10) across 96 cell lines. TPM, binary, z-score views. Chumakov 2018 IFN integrity toggle (28 genes). Colorblind-safe Cividis mode. 6-tier data sourcing.
2018–2019First-party RNA-seq: Mesothelioma (7 lines + 2 LP-9) and Ovarian (11 lines + OEpi). FPKM expression, log₂FC, DESeq2. Receptor genes, IFN response, and Chumakov 2018 IFN Integrity (28 genes).
2018–2019First-party RNA-seq: mesothelioma (7 + LP-9, Set B) and ovarian (11 + OEpi, Sets E/F). F11R/ITGB3 CCLE discrepancies, ISG induction, Chumakov 28-gene panel, QC corrections (label swaps, EKAZ). Cross-panel findings.
202628-gene IFN integrity panel across 64 lines (20 RNA-seq + 44 CCLE). cGAS silenced 23% pan-cancer. IRF9 80% depleted. Three-tier CDx. DES calibration.
2019–2020ELISA + WB. r = −0.028 — not predictive of OV kill. Reinterpreted as immune contexture marker for OV + anti-PD-1 combination.
20265-gene protease panel across 61 lines. STR0028 (Sendai Moscow) protease-independent — kills regardless. STR0030 (Sendai Cantell) requires proteases and fails in protease-negative lines.
2026Why Sator RNA-seq and CCLE produce different prognostic signals. Culture condition effects on metabolic genes, genetic drift (Ben-David 2018), receptor stability vs metabolic dynamics. 57% R²adj loss quantified.
Pathway-centric resistance analysis, gene pair CDx candidates, cancer-type-specific drivers, literature validation, and treatment strategies for resistant tumors.
Genome-wide resistance analysis: 189 pathway genes × 69 cell lines × 38 viruses. 17 viral lifecycle pathways, gene pair predictions (R²adj=0.68), cancer-type-specific drivers, per-cell-line resistance signatures. Literature IFN combos tested. Cividis colorblind mode.
2026Same 189-gene × 17-pathway analysis using only CCLE/DepMap expression data. Independent validation of prognostic findings without Sator RNA-seq. Zero pathways reach significance in CCLE-only (vs 5 in mixed-source) — the Sator RNA-seq provides unique predictive power.
2026Peer-reviewed validation of all Prognostic Explorer findings against 30 published studies. 17 pathways scored, 7 cancer-specific markers checked, metabolic reprogramming and gene pair models assessed. 4 Chart.js interactive charts, clickable PMC PDF links, graduate-level plain-language explainers.
2026Side-by-side comparison of CCLE-only (60 lines) vs mixed-source (69 lines) prognostic explorers. 57% R²adj drop without Sator RNA-seq. Autophagy signal collapses (p=0.003→0.868). MCL1 melanoma confirmed across both. 5 tabs: pathway comparison, cancer-type markers, cross-virus stability.
2026Quantitative comparison of 177 genes in the prognostic panel between CCLE (n=60) and Sator RNA-seq (n=21). 91 genes (51%) change correlation direction between platforms. 8 genes show major disagreements (|Δρ| > 0.5). Identifies which findings are platform-stable vs condition-dependent. Interactive sortable table with 3 tabs: divergent genes, methodology, implications.
2026Full statistical methods: Spearman correlations, FDR correction, pairwise regression, Mann-Whitney DE, pathway activity scores. All tables with p-values and effect sizes. Overfitting assessment. IFN-β response analysis.
2026Graduate-level narrative: why autophagy/trafficking drive OV resistance (not IFN). Gene pairs as CDx candidates. Cancer-type-specific therapeutic strategies. Limitations and next steps.
2023Virus selection framework per cancer type. Cocktail design rationale. Clinical pathway mapping.
2026Why 13 tumors resist most viruses and how to overcome each one. Part 1: Molecular diagnosis via Chumakov 28-gene panel. Part 2: Individual treatment plans — sensor gaps, JAKi combos, sequential dosing.
2026Mixed-source (n=20) vs CCLE-only (n=60). Pathway p-value divergence, FCGRT+SOCS1 cross-validated pair, metabolic signal collapse. Side-by-side tables.
KNN receptor-expression model. 1,064 locked predictions (532 basal + 532 IFNβ). LOOCV-validated, SHA256-timestamped.
532 basal + 532 IFNβ locked KNN predictions for 14 untested validation cell lines. Click any cell for confidence tiers, neighbor details, receptor profile.
2026Predicted vs. observed comparison. 7 analysis tabs: scatter, confidence, virus family, cancer type, CDx binary, explorer. CSV upload.
Apr 20261,064 predictions (532 basal + 532 IFNβ) for 14 validation lines. K=3, z-score normalized, inverse-distance weighted. SHA256 timestamped before experiment.
Apr 2026Phase 1 (7 lines screened): ACHN, Caco-2, FaDu, NCI-H460, HepG2, PC-3, U87MG. Phase 2 (7 pending): A549, HCT116, HT-29, 786-O, HeLa, SCC-25, Huh-7.5.
2024Receptor–kill correlations across 96 cell lines. Three-tier CDx framework. PBMC selectivity index. Per-virus Pearson r values.
In vivo evidence, production optimization, and manufacturing feasibility.
CoxB2/CoxB3 cross species barrier on AB1 (89%/88%). CoxA7 kills 95% SoloGlio GBM. Syngeneic model enabled.
2023–2025Xenograft results: 6-arm combination study (SATOR Combined best), MSTO-211H vs T-VEC (STR-0011 superiority, p<0.05, >2× volume difference). Head-to-head win over FDA-approved OV.
2021VERO cells, Capto Core 700, RT-PCR titration. ~10¹⁰ particles/mL. Manufacturing feasibility confirmed.
2020–2024Egg-based propagation. Multi-batch titer (2020 vs 2024). 341 vials. Bioactivity validation + hybrid construct.
Market opportunity, go-to-market planning, and investor-ready materials.
Full-page scrolling narrative. Platform thesis, 38-virus library, embedded pancreatic heatmap, pipeline & clinical evidence, business model.
Mar 202628-slide PPTX. Market opportunity, OV science, meso lead indication, in vivo + human evidence, competitive landscape, IP, pipeline, $12M Pre-A ask.
2025Data moat, CDx thesis, competitive landscape, IP strategy, pipeline, financials. Printable text format.
Mar 202613-slide PPTX. Technical deep-dive: screening methodology, receptor biology, KNN model, RNA-seq, manufacturing readiness.
2024Gap analysis, CDx regulatory path, clinical trial design, manufacturing scale-up, competitive landscape.
Non-specialist explanations of every major component. Written for investors and collaborators.
Tab-by-tab walkthrough of the interactive visualizer. Controls (dark mode, colorblind, virus names), sidebar filters, heatmap column drag, gene combinations, cancer type resistance, cell line profiles. How to read all statistics.
2026How to navigate the kill heatmap, receptor expression, and compare tabs. Toggle buttons, sorting, IFN modes, predictions overlay, colorblind mode, and practical tips.
2026How to read dose-response curves, compare profiles, understand curve shapes, assess potency, and interpret combination synergy data.
2026The four-layer companion diagnostic: receptors, IFN integrity, phenotypic assay, proteases. How we match viruses to tumors.
2026Step-by-step prediction algorithm. 16-gene receptor panel, z-score normalization, K=3, inverse-distance weighting, LOOCV validation.
2026Why we test every virus twice. Sensitivity zones, cancer-type patterns, the immune primer paradox, virus selection implications.
2026How cancer cells lose antiviral defenses. The relay race: detection, signaling, response. cGAS silencing, MDA5 variation, IRF9 bottleneck.
Protocols, methodology documentation, and reference materials.
Every asset in this portal carries a classification badge. This legend defines the system.